Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine +/- Azithromycin in COVID-19
NCT04344444Phase 3Terminated
- Sponsor
- LCMC Health
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by LCMC Health. Primary endpoint: Most severe outcome at 5 days. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04344444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344444.